Patent Claims

Pharmaceutical formulation, containing a xanthogenate of formula I

irritating effect.

$$R_1-O-C$$
 $S-R_2$
(1)

wherein R_1 represents an optionally substituted aryl or alkyl residue, and R_2 represents a metal atom, an optionally substituted alkyl, alkoxy, amino or ammonium group or halogen, and an inhibitor of viral nucleic acid replication, and optionally an adjuvant enhancing the activity of the xanthogenate and a carrier substance reducing the

- 2. Pharmaceutical formulation according to claim 1, **characterized in that** R₁ is an adamantyl, norbornyl, tricyclodecyl, benzyl, linear or branched C₃-C₂₀ alkyl, C₃-C₂₀ cycloalkyl, furyl, pyridyl, anthracyl, naphthyl, phenanthryl, perinaphthyl or quinuclidinyl residue, whereby the aforementioned linear or branched C₃-C₂₀ alkyl residue can be substituted by a hydroxyl, a C₁-C₄ alkoxy group, a halogen atom or an amino group, and the aforementioned C₃-C₂₀ cycloalkyl residue can also be substituted by a hydroxyl, a C₁-C₄ alkoxy or a C₁-C₄ alkyl group, a halogen atom or an amino group.
- 3. Pharmaceutical formulation according to claim 2, **characterized in that** R₁ is a cyclododecyl, dodecyl, undecyl, decyl, tricyclo[5,2,1,0^{2,6}]-decyl, nonyl, octyl, bicyclo[2,2,1]-heptyl, cyclohexyl, hexyl or toluyl residue.
- Pharmaceutical formulation according to any one of the claims 1 to 3,
 characterized in that R₂ is a sodium or potassium atom or a dimethylglycylester or methylester group.

- Pharmaceutical formulation according to any one of the claims 1 to 4,
 characterized in that the inhibitor of viral nucleic acid replication is a nucleoside analogue.
- 6. Pharmaceutical formulation according to claim 5, **characterized in that** the inhibitor of viral nucleic acid replication is selected from aciclovir, valaciclovir, penciclovir, and famciclovir.
- 7. Pharmaceutical formulation according to any one of the preceding claims, characterized in that it contains 1 to 10, preferably 2 to 4 parts inhibitor of viral nucleic acid replication per one part xanthogenate.
- 8. Pharmaceutical formulation according to any one of the claims 1 to 7, characterized in that it contains an ionic detergent as adjuvant, preferably a fatty acid with 6 to 19 C atoms or an alkylsulphate with 8 to 18 C atoms.
- Pharmaceutical formulation according to any one of the claims 1 to 7,
 characterized in that it contains deoxycholic acid or a pharmaceutically tolerable salt thereof as adjuvant.
- 10. Pharmaceutical formulation according to any one of the claims 1 to 7, characterized in that it contains a phosphonic acid as adjuvant.
- 11. Pharmaceutical formulation according to claims 1 to 10, **characterized in that** it contains, in addition, cholesterol as carrier substance.
- 12. Agent for the treatment of viral, tumor or autoimmune diseases, **characterized in that** it contains a pharmaceutical formulation according to at least one of the
 claims 1 to 11.

- 13. Agent according to claim 12, **characterized in that** it contains tricyclo[5,2,1,0^{2,6}]-decane-9-yl-xanthogenate as xanthogenate, cholesterol or phosphatidylcholine as carrier substance, the sodium or potassium salt of decanoic acid as adjuvant, and the inhibitor of viral nucleic acid replication is selected from aciclovir, valaciclovir, penciclovir, and famciclovir.
- 14. Agent according to claim 13, **characterized in that** it contains aciclovir as inhibitor of viral nucleic acid replication.
- 15. Agent according to at least one of the claims 12 to 14, **characterized in that** it contains one part xanthogenate, one part inhibitor of viral nucleic acid replication, four parts carrier substance, and one part adjuvant.
- 16. Agent according to at least one of the claims 12 to 14, **characterized in that** it is an ointment that contains the pharmaceutical formulation in a lipophilic substance, preferably vaseline.